Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3546894 | 0.94 | BCHE (0.74) | BCHEADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL14307357 | 0.94 | BCHE (0.74) | BCHEADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL13344580 | 0.94 | BCHE (0.74) | BCHEADRB2ADRB1ADRB3KDM4E | |
| Hydrochloric Acid SCHEMBL5097169 | 0.93 | BCHE (0.72) | BCHEADRB2ADRB1ADRB3KDM4E | |
| Oxalic Acid SCHEMBL3548726 | 0.93 | BCHE (0.69) | BCHEADRB2ADRB1ADRB3KDM4E | |
| Oxalic Acid SCHEMBL6186341 | 0.92 | BCHE (0.67) | BCHEADRB2ADRB1ADRB3KDM4E | |
| Oxalic Acid SCHEMBL3544096 | 0.92 | BCHE (0.67) | BCHEADRB2ADRB1ADRB3KDM4E | |
| Oxalic Acid SCHEMBL3548498 | 0.92 | BCHE (0.61) | BCHEADRB2ADRB1ADRB3KDM4E | |
| Oxalic Acid SCHEMBL5094543 | 0.89 | BCHE (0.67) | BCHEKDM4EMAPTPKM | |
| Oxalic Acid SCHEMBL3546925 | 0.88 | BCHE (0.71) | BCHEKDM4EMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033007-A1 | Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy | MILLER DUANE D | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033007-A1 | Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy | BAD, TP53, MCL1 | BCHE 2608/4885ADRB2 4360/4885ADRB1 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.